Tele: 561.316.3330
Breaking Medical Device News

Friday, October 15, 2021
HomeOwlstone MedicalOwlstone Medical Establishes Scientific Advisory Board with Appointment of Professor Sir Bruce...

Owlstone Medical Establishes Scientific Advisory Board with Appointment of Professor Sir Bruce Ponder

Sir Bruce Ponder

Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “With over four decades’ work in cancer research we are honoured that Professor Sir Bruce Ponder is joining our SAB. His tremendous depth of experience and knowledge will be hugely valuable to Owlstone Medical as we develop our Breath Biopsy platform for early detection of cancer and realize our ambition to save 100,000 lives and $1.5B in healthcare costs.”

Owlstone Medical, (a diagnostics company developing a breathalyzer for disease), announced today the appointment of Professor Sir Bruce Ponder FRCP FMedSci FRS to its newly established Scientific Advisory Board (SAB) with immediate effect. The SAB will form a key strategic resource, providing unique research perspectives and clinical expertise as the company introduces a new non-invasive diagnostic modality focused on cancer, inflammatory disease and infectious disease.

Professor Sir Bruce Ponder is Emeritus Professor of Oncology at the University of Cambridge and was the inaugural director of the Cancer Research UK Cambridge Institute (CRUKCI). He was knighted for Services to Medicine in the 2008 and was awarded the 2013 Cancer Research UK Lifetime Achievement Prize.

Professor Sir Bruce Ponder has made enormous contributions to the field of oncology, including setting up one of the first specialist clinics for families with cancer, involvement in the discovery of several genes predisposing to cancer, and advances in our understanding of how cancer develops. His group at the CRUKCI is investigating how variations in multiple genes combine to contribute to susceptibility to breast and lung cancer, with the aim to identify high risk groups for targeted cancer screening and prevention.

Billy Boyle, co-founder and CEO at Owlstone Medical, commented: “With over four decades’ work in cancer research we are honoured that Professor Sir Bruce Ponder is joining our SAB. His tremendous depth of experience and knowledge will be hugely valuable to Owlstone Medical as we develop our Breath Biopsy platform for early detection of cancer and realize our ambition to save 100,000 lives and $1.5B in healthcare costs.”

Professor Sir Bruce Ponder added: “There is a great need to detect cancer earlier, and I strongly believe that Owlstone Medical’s technology enabling non-invasive diagnosis through breath can make a big difference in our approach to cancer screening. I am excited to be contributing to the growth and future direction of Owlstone Medical.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy